A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

Hartmut J. Ehrlich, Markus Müller, Helen May‐Lin Oh, +12

New England Journal of Medicine

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

Sven Björkman, Myungshin Oh, Gerald Spotts, +7

Blood

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Joan Cox Gill, Giancarlo Castaman, Jerzy Windyga, +9

Blood

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial

Nina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, +21

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccine DevelopmentDose-escalation Phase 1/2Vaccine Research +7

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

Perry Barrett, Gregory P. Berezuk, Sandor Fritsch, +5

The Lancet

VaccinologyVaccine SafetyCross-protectionVaccinationVaccine Development +7

Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency

Joseph A. Church, Heinz Leibl, Mark R. Stein, +11

Journal of Clinical Immunology

Primary ImmunodeficiencyNew 10Autoimmune DiseaseImmunodeficienciesImmunology +8

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Daniel Suez, Mark R. Stein, Sudhir Gupta, +10

Journal of Clinical Immunology

Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN^®0.5 ml in adults aged 18-67 years

Alexandra Loew-Baselli, Eva-Maria Poellabauer, Borislava G. Pavlova, +5

Human Vaccines

Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity

Hartmut J. Ehrlich, Borislava G. Pavlova, Sandor Fritsch, +7

Vaccine

VaccinationVaccine SafetyVaccine DevelopmentMedicineVaccine Surveillance +6

A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses

Hartmut J. Ehrlich, Markus Müller, Sandor Fritsch, +11

The Journal of Infectious Diseases